Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927459 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol
A Phase 1 study, sponsored by Arbutus Biopharma Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00927459 is a Phase 1 study that was terminated before completion, run by Arbutus Biopharma Corporation. The registered enrollment target is 23 participants.
The verdict
NCT00927459, a Phase 1 study, was terminated before completion, sponsored by Arbutus Biopharma Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.
Interventions
- DRUG Placebo
- DRUG PRO-040201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927459
The ClinicalTrials.gov registry entry for NCT00927459 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbutus Biopharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00927459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00927459 about?
NCT00927459 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol". This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.
What is the current status of trial NCT00927459?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2009-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00927459?
The interventions under investigation include: Placebo (DRUG), PRO-040201 (DRUG).
Who is sponsoring clinical trial NCT00927459?
This trial is sponsored by Arbutus Biopharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.